SELLAS Life Sciences/$SLS

1D1W1MYTD1Y5YMAX

About SELLAS Life Sciences

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Ticker
$SLS
Sector
Health
Primary listing
NASDAQ
Employees
-
Headquarters
New York, United States
Website
sellaslifesciences.com

SLS Metrics

BasicAdvanced
$2.3B
-
-$0.21
2.49
-

Bulls say / Bears say

REGAL is approaching its pre-specified 80th event, which will trigger the final efficacy analysis of GPS in AML. If the result is positive, SELLAS says it could support a Biologics License Application, creating a near-term late-stage catalyst. (AP News, Last10K)
SELLAS reported encouraging earlier clinical data for SLS009: a 46% overall response rate among 35 evaluable relapsed or refractory AML patients, with no dose-limiting toxicities or treatment-related deaths. It is now testing the drug in earlier-line AML, which could broaden its commercial opportunity if the signal holds up. (GlobeNewswire)
SELLAS had $138.3 million in cash and cash equivalents at 30 June 2026. That gives the company a stronger near-term funding base while it advances the REGAL and SLS009 programmes towards their key read-outs. (AP News, Last10K)
The lead asset remains a binary clinical bet, and the company is still blinded to the REGAL outcome. The reported 80-event milestone starts database lock, review and statistical analysis; it does not itself show that GPS improves survival. (Last10K, AP News)
SLS009 is not yet a proven second growth engine: only 28 of 80 patients had been enrolled in the frontline AML Phase 2 study by the August update. Its pancreatic-cancer opportunity is earlier still, based on preclinical models rather than human efficacy or safety data. (AP News, GlobeNewswire)
The stronger cash position has come with dilution: large warrant exercises increased the share count, while a $150 million at-the-market facility remains available. Further equity issuance could reduce each existing shareholder’s claim on any future success. (StockTi, Last10K)
Data summarised monthly by Lightyear AI. Last updated on 19 Sept 2026.

SLS News

AllArticlesVideos

When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges

Benzinga1 month ago

SELLAS Life Sciences Shares Slip Wednesday as Price Tests $16 Resistance Wall

Benzinga3 months ago

SELLAS Life Sciences Shares Fall Tuesday: What's Driving The Move?

Benzinga3 months ago

Funds containing SLS

AllEURGBPUSD
Funds
Fund name
Fund size
$SLS weighting
SPDR Russell 2000 US Small Cap€R2US
€4.8B0.08%
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG
€2.8B0.04%
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1
£2.4B0.04%
iShares MSCI World Small Cap$WSML
$9B0.02%
iShares MSCI World Small Cap€IUSN
€7.8B0.02%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.